THE EMBODIMENTS OF THE INVENTION IN WHICH AN EXCLUSIVE PROPERTY OR PRIVILEGE IS CLAIMED ARE AS FOLLOWS:

1. A process of making a solid pharmaceutical composition comprising moexipril magnesium, said process comprising the step of reacting moexipril or an acid addition salt thereof with an alkaline magnesium compound in the presence of a solvent so as to convert most or all of the moexipril or moexipril acid addition salt to moexipril magnesium.

2. A process of Claim 1 comprising the steps of:

   i) Adding the moexipril or acid addition salt thereof and the alkaline magnesium compound to solvent and mixing in the liquid state;

   ii) Evaporating the solvent to obtain a dried material, and

   iii) Further processing the dried material into the solid pharmaceutical composition.

3. A process of Claim 2 wherein, before the solvent is evaporated, the liquid is filtered to remove unreacted alkaline magnesium compound.

4. A process of Claim 2 or 3 wherein the solvent is evaporated by spray-drying.

5. A process of Claim 1 comprising the steps of:

   i) adding the moexipril or acid addition salt thereof and the alkaline magnesium compound to solvent;

Sub A1

ii) using the resultant solution or suspension to wet granulate other excipients to obtain a wet mass;

iii) drying the wet mass to obtain a dried mass; and

iv) further processing the dried mass into the solid pharmaceutical composition.

6. A process of Claim 1 comprising the steps of:

i) adding the alkaline magnesium compound to solvent;

ii) using the resulting solution or suspension to wet granulate a mixture of the moexipril or acid addition salt thereof and one or more excipients to obtain a wet mass;

iii) drying the wet mass to obtain a dried mass; and

iv) further processing the dried mass into the solid pharmaceutical composition.

7. A process of Claim 1 comprising the steps of:

i) adding the moexipril or acid addition salt thereof to solvent;

ii) using the resultant solution or suspension to wet granulate a mixture of the alkaline magnesium compound and one or more other excipients to obtain wet mass;

iii) drying the wet mass to obtain a dried mass, and

iv) further processing the dried mass into the solid pharmaceutical composition.

8. A process of Claim 1 comprising the steps of:

i) mixing the moexipril or acid addition salt thereof and alkaline magnesium compound with one or more other excipients;

ii) adding a solvent and mixing to obtain a wet mass;

iii) drying the wet mass to obtain a dry mass; and

iv) further processing the dried mass into the solid pharmaceutical composition.

9. A process of any of Claims 1 to 8 where the solvent is selected from a group of solvents comprising water, an organic solvent, acetone, or combinations thereof.

10. A process of any of Claims 1 to 8 wherein the moexipril or acid addition salt thereof is moexipril hydrochloride.

Sub A1

11. A process of any of Claims 1 to 8 wherein the alkaline magnesium compound is selected from the group of compounds comprising magnesium hydroxide, magnesium oxide, magnesium carbonate, or the magnesium salt of a weak acid.

12. A process of any of Claims 1 to 8 wherein the percentage of the moexipril or acid addition salt converted to moexipril magnesium is substantially greater than about 80%.

13. A process of any of Claim 12 wherein the percentage of the moexipril or acid addition salt thereof converted to moexipril magnesium is substantially greater than 90%.

14. A solid pharmaceutical composition comprising moexipril magnesium.

Add A2